Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor.

Seol HS, Kang HJ, Lee SI, Kim NE, Kim TI, Chun SM, Kim TW, Yu CS, Suh YA, Singh SR, Chang S, Jang SJ.

Cancer Lett. 2014 Apr 1;345(1):56-64. doi: 10.1016/j.canlet.2013.11.010. Epub 2013 Dec 11. Erratum in: Cancer Lett. 2014 Jul 10;349(1):96. Kang, Hyojeong [corrected to Kang, Hyo Jeong].

PMID:
24333725
2.

A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells.

Puig I, Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argilés G, Vivancos A, Tabernero J, Rojas S, Palmer HG.

Clin Cancer Res. 2013 Dec 15;19(24):6787-801. doi: 10.1158/1078-0432.CCR-12-1740. Epub 2013 Oct 29.

3.

Genomic profiling of patient-derived colon cancer xenograft models.

Lee WS, Kim HY, Seok JY, Jang HH, Park YH, Kim SY, Shin DB, Hong S.

Medicine (Baltimore). 2014 Dec;93(28):e298. doi: 10.1097/MD.0000000000000298.

4.

A patient-derived xenograft mouse model generated from primary cultured cells recapitulates patient tumors phenotypically and genetically.

Seol HS, Suh YA, Ryu YJ, Kim HJ, Chun SM, Na DC, Fukamachi H, Jeong SY, Choi EK, Jang SJ.

J Cancer Res Clin Oncol. 2013 Sep;139(9):1471-80. doi: 10.1007/s00432-013-1449-6. Epub 2013 Jul 2.

PMID:
23817694
5.

Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.

Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, Anderson S, Moskalev I, Haegert A, Alshalalfa M, Erho N, Davicioni E, Fazli L, Li E, Collins C, Wang Y, Black PC.

Oncotarget. 2015 Aug 28;6(25):21522-32.

6.

NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : a model for stromal cell-tumor cell interaction for human colon cancer.

Maykel J, Liu JH, Li H, Shultz LD, Greiner DL, Houghton J.

Dig Dis Sci. 2014 Jun;59(6):1169-79. doi: 10.1007/s10620-014-3168-5. Epub 2014 May 6.

7.

MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.

Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, De Bacco F, Menietti E, Han M, Rideout WM 3rd, Perera T, Bertotti A, Trusolino L, Comoglio PM, Boccaccio C.

Cancer Res. 2014 Mar 15;74(6):1857-69. doi: 10.1158/0008-5472.CAN-13-2340-T. Epub 2014 Jan 21.

8.

Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer.

Porru M, Artuso S, Salvati E, Bianco A, Franceschin M, Diodoro MG, Passeri D, Orlandi A, Savorani F, D'Incalci M, Biroccio A, Leonetti C.

Mol Cancer Ther. 2015 Nov;14(11):2541-51. doi: 10.1158/1535-7163.MCT-15-0253. Epub 2015 Aug 24.

9.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

10.

Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors.

Cho YB, Hong HK, Choi YL, Oh E, Joo KM, Jin J, Nam DH, Ko YH, Lee WY.

J Surg Res. 2014 Apr;187(2):502-9. doi: 10.1016/j.jss.2013.11.010. Epub 2013 Nov 15.

PMID:
24332554
11.

KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers.

Chen EC, Karl TA, Kalisky T, Gupta SK, O'Brien CA, Longacre TA, van de Rijn M, Quake SR, Clarke MF, Rothenberg ME.

Gastroenterology. 2015 Sep;149(3):705-17.e2. doi: 10.1053/j.gastro.2015.05.042. Epub 2015 May 28.

12.

Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors.

Gupta J, Igea A, Papaioannou M, Lopez-Casas PP, Llonch E, Hidalgo M, Gorgoulis VG, Nebreda AR.

Oncotarget. 2015 Apr 20;6(11):8539-51.

13.

Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features.

Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, Saulnier P, Judde JG, Janneau JL, Auger N, Validire P, Dutrillaux B, Praz F, Bellet D, Poupon MF.

Cancer Res. 2007 Jan 1;67(1):398-407.

14.

The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.

Michaelson JS, Kelly R, Yang L, Zhang X, Wortham K, Joseph IB.

Cancer Biol Ther. 2012 Jul;13(9):812-21. Epub 2012 Jun 6.

PMID:
22669574
15.

A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.

Klinghammer K, Raguse JD, Plath T, Albers AE, Joehrens K, Zakarneh A, Brzezicha B, Wulf-Goldenberg A, Keilholz U, Hoffmann J, Fichtner I.

Int J Cancer. 2015 Jun 15;136(12):2940-8. doi: 10.1002/ijc.29344. Epub 2014 Nov 26.

16.

Microsatellite instable and microsatellite stable primary endometrial carcinoma cells and their subcutaneous and orthotopic xenografts recapitulate the characteristics of the corresponding primary tumor.

Schrauwen S, Coenegrachts L, Depreeuw J, Luyten C, Verbist G, Debruyne D, Vergote I, Lambrechts D, Amant F.

Int J Gynecol Cancer. 2015 Mar;25(3):363-71. doi: 10.1097/IGC.0000000000000363.

PMID:
25695543
17.

Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors.

Bondarenko G, Ugolkov A, Rohan S, Kulesza P, Dubrovskyi O, Gursel D, Mathews J, O'Halloran TV, Wei JJ, Mazar AP.

Neoplasia. 2015 Sep;17(9):735-41. doi: 10.1016/j.neo.2015.09.004.

18.

Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model.

Valdez KE, Fan F, Smith W, Allred DC, Medina D, Behbod F.

J Pathol. 2011 Dec;225(4):565-73. doi: 10.1002/path.2969. Epub 2011 Sep 26.

19.

Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.

Lee HW, Lee JI, Lee SJ, Cho HJ, Song HJ, Jeong DE, Seo YJ, Shin S, Joung JG, Kwon YJ, Choi YL, Park WY, Lee HM, Seol HJ, Shim YM, Joo KM, Nam DH.

Clin Cancer Res. 2015 Mar 1;21(5):1172-82. doi: 10.1158/1078-0432.CCR-14-1589. Epub 2014 Dec 30.

20.

[Establishment and its biological characteristics of patient-derived lung cancer xenograft models].

Zhuo Y, Wu Y, Guo A, Chen S, Su J.

Zhongguo Fei Ai Za Zhi. 2010 Jun;13(6):568-74. doi: 10.3779/j.issn.1009-3419.2010.06.020. Chinese.

Supplemental Content

Support Center